depcomswinnerscircle@gmail.com
Followers | 118 |
Posts | 10,219 |
Boards Moderated | 2 |
Alias Born | 06/08/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still holding my FRZT might add this week.
Sorry to hear that Fitz. Been laying low myself. Just got some funds today, not sure what I'm going to do. I used my sharebuilder account today to buy more NVDA AND EXC. I use sharebuilder plan once a month to build long term plays.
Hey Fitzgerald hope your doing well. What's going on?
Another Article 3 hours ago on Stock News Union
Garfield Go Game Debuts
http://stocknewsunion.com/freeze-tag-inc-otcmktsfrzts-garfield-go-game-debuts/5673/
Garfield Go Article out 11 hours ago as well on Heavy.com
'Garfield Go' Five Fast Facts You Need To Know
http://heavy.com/games/2017/06/garfield-go-game-pokemon-paws-inc-jim-davis-ar-augmented-reality-android-iphone/
Nice! PR out already this morning.
$FRZT Ready to Move
Freeze Tag Announces Garfield GO Marketing Plans
Source: InvestorsHub NewsWire
New Game Garfield GO To Launch Tomorrow
TUSTIN, CA - June 12, 2017 - InvestorsHub NewsWire - Freeze Tag (OTC: FRZT), a leading creator of mobile social games, today announced marketing plans for its new Garfield GO, a free-to-play, augmented reality treasure hunting game.
Were excited to announce our marketing plans to all of the fans who are anticipating the launch of the first augmented reality Garfield adventure, said Craig Holland, CEO of Freeze Tag. Word-of-mouth promotion will be an important part of the marketing of the game, so we invite Garfield and Freeze Tag fans everywhere to download and share the game with their friends.
Freeze Tag disclosed that the Garfield GO marketing plans include coordinating press releases with Paws Inc. and social media postings with Paws on the Garfield Facebook and Twitter feeds. Freeze Tag will be running Facebook advertising promotions and an email promotional campaign to their database of gamers. In addition, strategic partner Munzee is promoting the Garfield GO game to their active player base across the USA and Canada.
The Garfield GO! mobile game is the first collaboration between Freeze Tag and strategic partner, Munzee the next generation in global scavenger hunt games. To learn more about Munzee, go to www.munzee.com.
To learn more about Garfield GO, please visit the games website at www.garfieldgo.com.
About GARFIELD
GARFIELD was born on the comics pages on June 19, 1978. The creation of cartoonist Jim Davis, GARFIELD is a humorous strip centered on the lives of a quick-witted orange cat who loves lasagna, coffee, and his remote control; Jon Arbuckle, his owner; and Odie, a sweet but dumb dog. GARFIELD was introduced to the world in just 41 newspapers and is now the most widely syndicated comic strip ever, appearing in 2100 newspapers. The strip, distributed by Universal Press, is read by over 220 million people each day and is translated into 42 languages.
Follow Garfield on Facebook (facebook.com/Garfield), Twitter (twitter.com/Garfield), Instagram (instagram.com/garfield_real) and YouTube (youtube.com/garfieldandfriends), and visit garfield.com, and Garfields free educational site, professorgarfield.org.
About MUNZEE Inc.
With almost 6 million locations worldwide and hundreds of thousands of players, Munzee is a social platform that blends gamification, geolocation and marketing elements into an experience that rewards players for going places in the physical world. Utilizing QR code and GPS technology, Munzee is able to validate a persons location and provide them points to level up in the various Munzee mobile applications. The Munzee suite of applications includes Munzee, our flagship product, Eventzee, a photo scavenger hunt useful for corporate training and trade shows, and WallaBee, an addictive collecting game with over 2,000 beautifully drawn digital cards.
About Freeze Tag, Inc.
Freeze Tag, Inc. is a leading creator of mobile social games that are fun and engaging for all ages. Based on a free-to-play business model that has propelled games like Pokemon Go and Candy Crush Saga to worldwide success, we employ state-of-the-art data analytics and proprietary technology to dynamically optimize the gaming experience for revenue generation. Players can download and enjoy our games for free, or they can purchase virtual items and additional features within the game to increase the fun factor. Our games encourage players to compete and engage with their friends on major social networks such as Facebook and Twitter. Founded by gaming industry veterans, Freeze Tag has launched several successful mobile games including the number one hit series Victorian Mysteries and Unsolved Mystery Club, as well as digital entertainment like Etch A Sketch. Freeze Tag games have been downloaded millions of times on the Apple, Amazon and Google app stores.
Contact:
info@freezetag.com
714-210-3850 x26
There's the PR just posted news.
$DCTH at .021
Found a bottom at .21 and moved up last two days. Granted .24 is a world beater but it's a positive move back up.
DXTR can still rebound back to the .75-.80 pps level. It has stabilized for last two days and people need to feel it's going to hold before they add. The .21 seems to be the bottom at this point.
Still not a .22 stock. Good opportunity to add before it goes back up.
Perfect bottom bounce play
See if we can close at .25 or better but at least green.
Looks like we're getting some bid building and more stability. Good to see. A move up is in order, this stick is definitely worth more that .21
$CLSN conference call in progress and up 9% so far today.
FIRST QUARTER CONFERENCE CALL on. Financial results STARTED AT 11
$DXTR great opportunity for a double off bottom here of .24
$CLSN - Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017
Source: GlobeNewswire Inc.
Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system at 11:00 a.m. EDT on Friday, May 12, 2017. To participate in the call, interested parties may dial 1-888-282-4591 (Toll-Free/North America) or 1-719-457-2605 (International/Toll) and ask for the Celsion Corporation 1st Quarter 2017 Earnings Call (Conference Code: 4060768) to register ten minutes before the call is scheduled to begin. The call will also be broadcast live over the internet at www.celsion.com.
The call will be archived for replay on Friday, May 12, 2017 and will remain available until Friday, May 26, 2017. The replay can be accessed at 1-888-203-1112 (Toll-Free/North America) or 1-719-457-0820 (International/Toll) using Conference Code: 4060768. An audio replay of the call will also be available on the Company’s website, www.celsion.com, for 90 days after 2:00 p.m. EDT on Friday, May 12, 2017.
About Celsion Corporation
Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
$CLSN up this am. Conference call due to start soon on financials / quarterly.
$DXTR - Didn't see the overnight dip coming but gave me an opportunity to load at the ground at .24 but this is really undervalued at .24
$DXTR 52 week high was $3.23 looking for bottom bounce of todays 52 week low. Low 8 million float and extremely thin. Target .80 to .90. Shouldnt take much volume for this to move. Currently trading at .51
Dextera Surgical, Inc. designs and manufactures proprietary stapling and anastomotic devices for cardiac and laparoscopic surgical procedures. Its technology portfolio is minimizes operating time and enable minimally-invasive and robot-assisted surgeries. The company manufactures and markets automated anastomosis systems, the C-Port Distal Anastomosis systems and PAS-Port Proximal Anastomosis system for coronary artery bypass graft surgery. Dextera Surgical was founded by Bernard A. Hausen and Stephen A. Yencho on October 15, 1997 and is headquartered in Redwood City, CA.
$DXTR 52 week high was $3.23 looking for bottom bounce of todays 52 week low. Low 8 million float and extremely thin. Target .80 to .90. Shouldnt take much volume for this to move.
$DXTR starter at .52 - 8 million shares in float and looking for bottom bounce here. target of .90
Took a position, can see this bouncing upward from here.
Somebody just bought premarket - 8,450 shares at $1.30
Not that I've seen.
The way I see it, we should be around at least $2, which for now is my target. It wasn't long ago that this was a $4 stock.
Grabbed some shares Friday at.86, it's up about 44%. Looked like a nice bottom bounce play.
$APTO bid support growing. Pre Market was hitting $1.30 but were holding $1.20 with no problem. Makes my target of $1.75 to $2 look attainable. Alerted at .86 as a bottom bounce play on Friday.
$RJDG volume a bit light so far, in at .02
$APTO holding $1 bid. First target $1.35 but looking for $1.75-$2
$APTO holding .96, some resistance at .97. WE know once we break $1 and hold it, the volume should come.
$APTO moving up steadily, holding bid support. Bottom bounce play entered on Friday at .86. Ask is now .94 with 12.74 shares outstanding as of December 16.
$APTO
Typo on my last post there are 12.74 million shares outstanding.
$APTO hits .92 after hours.
Alerted Friday at .86 as a bottom bounce play.
12.47 million shares outstanding.
Recently a $4 pps. First target $1.36.
Expecting this to hit $1.75 to $2 range
$APTO closed at .90. Looking next for that $1 break and bid support to hold at that level.
$APTO - 12.74 million shares outstanding
bottom bounce play
just passed 50/200 day moving average
alerted at .86 Friday
First target $1.36 but i would be looking for 1.75 to $1.86
This was $4 fairly recently
$APTO
Aptose is focused on the development of CG’806, an oral preclinical compound being developed for patients with FLT3-driven acute myeloid leukemia (AML) and certain BTK-driven B-cell malignancies.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
$APTO
Aptose Biosciences to Participate at the Bloom Burton & Co. Healthcare Investor Conference 2017
https://finance.yahoo.com/news/aptose-biosciences-participate-bloom-burton-123000637.html